This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study
to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days,
in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19
patients.